

The complete non-invasive solution for advanced liver disease assessment



The complete non-invasive solution for advanced liver disease management

Expand clinical capabilities with spleen stiffness measurement and ultrasound localization system.
Enhance exam efficiency with improved ergonomics and high-speed processing.

Powered by

LSM* by VCTE™

Liver Fibrosis

LSM by VCTE™ is unique, patented and validated for liver fibrosis assessment.

- It is the standard for non-invasive evaluation of liver stiffness.¹
- 3,300+ peer-reviewed publications support the use of LSM by VCTE™.

CAP™**

Liver Steatosis

CAP™ is unique, patented and validated for liver steatosis assessment.

- 900 international and peer-reviewed articles support the use of CAP™.^{2,3}

SSM* by VCTE™

Portal hypertension

SSM by VCTE™ is unique, patented and validated for portal hypertension assessment and can be used for risk stratification of patients with advanced CLD.⁴

- It is a new marker for non-invasive evaluation of spleen stiffness.
- 110+ peer-reviewed publications support the use of SSM by VCTE™

The new Baveno VII guidelines confirm the value of using FibroScan® for the management of patients with advanced chronic hepatitis, include the measurement of spleen stiffness (SSM by VCTE™), with the first associated diagnostic thresholds.

Baveno VII - R. de Franchis et al. Renewing consensus in portal hypertension. Journal of Hepatology 2022, vol. 76 | 959-974

*LSM: Liver Stiffness Measurement / SSM: Spleen Stiffness Measurement.

**Additional cost.



What makes FibroScan® unique?

Fast

A painless exam performed in less than 10 minutes to provide immediate results at the point-of-care.

Intuitive

Can be performed by any trained operator (physician, nurse).

Best in Class

The non-invasive gold standard solution validated by 3,500+ peer-reviewed publications and 160 international guidelines.

Reliable

Standardized examination with exceptional precision and reproducibility that can be utilized in 99% of patients.^{2,3}

Original

Equipped with patented technology and proprietary algorithms to deliver consistently accurate results.

When evidence matters and consistency counts

- **Pioneer** in the field of liver elastography
- FibroScan® produces biomarkers that can assess and monitor patients **over time**
- FibroScan® uses uniform algorithms that minimize **inter-operator variability** and eliminate **inter-system variability**
- **7,000+** FibroScan® installed worldwide enabling millions of liver examinations
- Winner of the Red Dot Design Award (FibroScan® 430 Mini+ model)





Optimize clinical workflows with real-time secure data transmission

Save time, secure data, and improve patient follow-up with FibroScan® Gateway. FibroScan® Gateway acts as an integration engine, automatically uploading and storing examinations to the EHR (Electronic Health Record).



Scores by echosens



Enhancing FibroScan® liver disease assessment with biological markers

Fast™

Identification of at-risk NASH patients

Agile 3+

Identification of advanced fibrosis in NAFLD patients

Agile 4

Identification of cirrhosis in NAFLD patients

Your everyday FibroScan® companion

Assess your patient's liver health in just a few clicks



MyFibroScan

Available on myfibroscan.com or on the myFibroScan app



FibroScan® by echosens

The non-invasive gold standard solution for comprehensive management of liver health

Which FibroScan® is right for you?



Capabilities	mini 430	mini+ 430	compact 530	expert 630
LSM by VCTE™	✓	✓	✓	✓
CAP™*		✓	✓	✓
SSM by VCTE™				✓
Features				
FibroScan® Gateway compatibility	✓	✓	✓	✓
MyFibroScan® compatibility	✓	✓	✓	✓
Embedded ultrasound localization system for assessment of obese or complex patients				✓
High-speed processing				✓
Integrated barcode reader				✓
Ergonomics				
Versatile and adaptive design: from transportable to cart-based device with dedicated roll stand			✓	
Fully transportable	✓	✓		
Battery-powered	✓	✓	✓	
Weight	5 kg	5 kg	10 kg	46 kg

*Additional cost



because liver health matters

- European Association for Study of Liver, Asociacion Latinoamericana para el Estudio del Hígado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-264. doi:10.1016/j.jhep.2015.04.006.
- Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol. 2017;66(5):1022-1030. doi:10.1016/j.jhep.2016.12.022
- Recio E, Cifuentes C, Macias J, et al. Interobserver concordance in controlled attenuation parameter measurement, a novel tool for the assessment of hepatic steatosis on the basis of transient elastography. Eur J Gastroenterol Hepatol. 2013;25(8):905-911. doi:10.1097/MEG.0b013e32835f4c3d
- Stefanescu H, Marasco G, Calès P, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020;40(1):175-185. doi:10.1111/liv.14228

Products in the FibroScan® range are Class IIa medical devices as defined by Directive 93/42/EEC (EC 0459). This device is designed for use in a medical practice in order to measure liver and spleen stiffness and ultrasound attenuation in patients with liver disease. Examinations with FibroScan® device shall be performed by an operator who has been certified by the manufacturer or its approved local representative. Operators are expressly recommended to carefully read the instructions given in the user manual and on the labelling of these products. Check cost defrayal conditions with paying bodies. Fast™, Agile 3+ and Agile 4 are in vitro diagnostic medical device according to directive 98/79/EC. Fast™, Agile 3+ and Agile 4 calculators are a tool for clinicians. Fast™ is computed from LSM and CAP (obtained from FibroScan® device) and AST blood parameter measurement, to aid in the identification of a patient with suspicion of NAFLD as being at risk for active fibrotic NASH (NASH+NAS≥4+F≥2). Fast™ was developed based on a prospective multicenter cohort and published in peer-reviewed literature. Agile 3+ is computed from LSM (obtained from FibroScan® device), AST, ALT, platelets, diabetes status, age and gender, to aid in the identification of patients with suspicion of NAFLD as having advanced fibrosis. Agile 4 is computed from LSM (obtained from FibroScan device), AST, ALT, platelets, diabetes status and gender, to aid in the identification of patients with suspicion of NAFLD as having cirrhosis. Agile 3+ and Agile 4 were developed based on a prospective multicenter cohort and published in peer-reviewed literature. These scores are presented as an educational service intended for licensed healthcare professionals. While these scores are about specific medical and health issues, they are not a substitute for or a replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions.